- Conditions
- Diabetes Mellitus Type 2
- Interventions
- DPP-IV Inhibitor, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 291 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 18
- States / cities
- Salinas, California • Clearwater, Florida • Hialeah, Florida + 15 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 151
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Glargine, LY2605541
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,538 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 66
- States / cities
- Anniston, Alabama • Mobile, Alabama • Chandler, Arizona + 63 more
- Conditions
- Type 2 Diabetes (T2DM)
- Interventions
- SGLT-2 inhibitor, GLP1-RA
- Drug
- Lead sponsor
- MaryAnn Banerji
- Other
- Eligibility
- 24 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Type1diabetes
- Interventions
- Artificial Pancreas Controller in Dual Hormone Mode, Artificial Pancreas Controller in Single Hormone Mode, Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode, XeriSol glucagon
- Device · Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 21 Years to 50 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Hypercholesterolaemia
- Interventions
- Alirocumab, Placebo, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 517 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 29
- States / cities
- Encino, California • Fresno, California • Oakland, California + 25 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- insulin degludec/insulin aspart, insulin glargine
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 465 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 24
- States / cities
- Fresno, California • Waterbury, Connecticut • Boynton Beach, Florida + 19 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Insulin glargine/Lixisenatide, Insulin glargine (HOE901), Background therapy
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 85
- States / cities
- Montgomery, Alabama • Little Rock, Arkansas • Anaheim, California + 63 more
- Conditions
- Cystic Fibrosis-related Diabetes, Cystic Fibrosis
- Interventions
- Empagliflozin, Placebo Control
- Drug · Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Heart Failure, Volume Overload
- Interventions
- Direct Sodium Removal Infusate 2.0
- Drug
- Lead sponsor
- Sequana Medical N.V.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Hyperglycemia, Cancer
- Interventions
- Diabetes, Control Group
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
- Interventions
- Pioglitazone study drug, Placebo, Pioglitazone Open Label
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Type 2 Diabetes Mellitus, Chronic Kidney Disease
- Interventions
- Fasiglifam, Placebo, Antihyperglycemic therapy
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 7
- States / cities
- Whittier, California • Westminster, Colorado • Tampa, Florida + 4 more
- Conditions
- Diabetic Nephropathies, Kidney Diseases, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
- Interventions
- Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Renin-angiotensin-aldosterone system blockade, Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Mineralocorticoid Receptor Antagonists(MRAs)
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- Insulin detemir, Dietary regimen
- Drug · Dietary Supplement
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 611 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 76
- States / cities
- Birmingham, Alabama • Ozark, Alabama • Anaheim, California + 63 more
- Conditions
- Obesity
- Interventions
- Behavioral Treatment, Placebo, Phentermine 15 MG
- Behavioral · Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Acute Kidney Injury
- Interventions
- SGLT2 inhibitor
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Hypertension, Diabetes Type 2
- Interventions
- Sitagliptin (DPP4 inhibitor), Substance P,, bradykinin, enalaprilat (ACE inhibitor), Glucagon-like peptide 1, brain natriuretic peptide
- Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies), Healthy Subjects (Treated With no Diabetes Therapies)
- Interventions
- exenatide, Other antidiabetic therapies, No diabetes therapy
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- Not listed
- Enrollment
- 363,766 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- LY2963016, Lantus, OAMs
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 759 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 28
- States / cities
- Montgomery, Alabama • Brooksville, Florida • Fort Lauderdale, Florida + 25 more
- Conditions
- Atherosclerosis
- Interventions
- Glipizide, rosiglitazone maleate
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 672 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 32 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Empagliflozin, DPP-4 inhibitor, GLP-1 receptor agonist
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- LY2963016, LANTUS®, Oral Antihyperglycemic Medication
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 493 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 10
- States / cities
- Miami, Florida • New Port Richey, Florida • Smyrna, Georgia + 7 more
- Conditions
- Polycystic Ovarian Syndrome in Adolescent Females, Obesity (Disorder)
- Interventions
- GLP-1 Receptor Agonists
- Drug
- Lead sponsor
- Nemours Children's Clinic
- Other
- Eligibility
- 12 Years to 18 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Kidney Disease, Chronic, Diabetes
- Interventions
- SGLT2 inhibitor
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas